Dr. Reddy’s Q4 Review - In Line Numbers; Focus On Launches, Cost to Continue: ICICI Direct
Workers pour in raw material to produce medicine capsules at Dr Reddy’s plant in Bachupally, Andra Pradesh. (Photographer: Amit Bhargava/Bloomberg News)

Dr. Reddy’s Q4 Review - In Line Numbers; Focus On Launches, Cost to Continue: ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Dr. Reddy's Laboratories Ltd.'s Q4 revenues grew 7.2% YoY to Rs 4,768 crore.

India sales grew 23.5% YoY to Rs 844 crore due to Wockhardt integration and new launches.

Europe revenues grew 14.8% YoY to Rs 396 crore amid new launches.

U.S. revenues de-grew 3.2% YoY to Rs 1,749 crore mainly due to Covid-19 related stocking in Q4 FY20.

Russia and other commonwealth of independent states sales grew 4% to Rs 593 crore.

Pharmaceuticals services and active ingredients segment grew 10% YoY to Rs 792 crore amid new product launches.

Click on the attachment to read the full report:

ICICI Direct Dr Reddys Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.